Missing content? – Request curation!
Request curation for specific Genes, Variants, or PubMed publications.
Have questions, comments, or suggestions? - Let us know!
Email us at : ckbsupport@genomenon.com
| Therapy Name | IBI3009 |
| Synonyms | |
| Therapy Description |
Limited information is currently available on IBI3009, a putative antibody-drug conjugate (ADC) (Sep 2024). |
| Drug Name | Trade Name | Synonyms | Drug Classes | Drug Description |
|---|---|---|---|---|
| IBI3009 | IBI-3009 | Limited information is currently available on IBI3009, a putative antibody-drug conjugate (ADC) (Sep 2024). |
| Molecular Profile | Indication/Tumor Type | Response Type | Therapy Name | Approval Status | Evidence Type | Efficacy Evidence | References |
|---|
| Clinical Trial | Phase | Therapies | Title | Recruitment Status | Covered Countries | Other Countries |
|---|---|---|---|---|---|---|
| NCT06613009 | Phase I | IBI3009 | Study of IBI3009 in Subjects With Unresectable, Locally Advanced or Metastatic Small Cell Lung Cancer and Other Neuroendocrine Carcinomas | Recruiting | AUS | 1 |